Literature DB >> 9663099

Photodynamic therapy of intracranial tissues: a preclinical comparative study of four different photosensitizers.

L Lilge1, B C Wilson.   

Abstract

OBJECTIVE: The effectiveness of four different photosensitizers for intracranial photodynamic therapy (PDT) of normal brain tissues and an intracranial tumor was investigated in rabbits, using the photodynamic threshold model.
SUMMARY: PDT is currently being investigated as an adjuvant treatment to surgical resection and/or radio chemotherapy of intracranial neoplasms. While possible neurotoxic side effects of the treatment have been noted, only limited preclinical data quantifying the response of intracranial normal and tumor tissues following PDT are available.
MATERIALS AND METHODS: The photodynamic threshold dose values for the four photosensitizers, Photofrin, 5-aminolevulinic acid (ALA)-induced Protoporphyrin IX (PpIX), Tin Ethyl Etiopurpurin (SnET2), and chloroaluminum phthalocyanine (AlClPc), were determined using measured light fluence distributions, photosensitizer concentration in tissue, and histologically-determined extent of necrosis following PDT. These measurements were made in normal rabbit brain and in an intracranially-implanted carcinoma (VX2).
RESULTS: For Photofrin, AlClPc, and SnET2 (in an emulsion delivery vehicle) normal grey and white matter were very sensitive to PDT, showing a significantly lower threshold dose value than VX2-tumor. For ALA-induced PpIX and SnET2 (in liposome) very little or no white matter damage was observed. Additionally, ALA-PpIX showed significantly lower concentration in white matter than in cortex and tumor. Normal brain structures lacking a blood-brain barrier showed high uptake of all photosensitizers and, hence, are at risk of collateral damage during PDT.
CONCLUSIONS: For clinical PDT of most adult intracranial neoplasms ALA-induced PpIX appears to be promising, and SnET2 (liposomal) has potential for selective tumor destruction with relative sparing of white matter. Other normal brain structures and, for the other photosensitizers, also white matter are at risk of collateral damage, if exposed to light during PDT.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9663099     DOI: 10.1089/clm.1998.16.81

Source DB:  PubMed          Journal:  J Clin Laser Med Surg        ISSN: 1044-5471


  23 in total

1.  An indwelling brachytherapy balloon catheter: potential use as an intracranial light applicator for photodynamic therapy.

Authors:  H Hirschberg; S Madsen; K Lote; T Pham; B Tromberg
Journal:  J Neurooncol       Date:  1999-08       Impact factor: 4.130

2.  Repetitive 5-aminolevulinic acid-mediated photodynamic therapy on human glioma spheroids.

Authors:  Steen J Madsen; Chung-Ho Sun; Bruce J Tromberg; Henry Hirschberg
Journal:  J Neurooncol       Date:  2003-05       Impact factor: 4.130

Review 3.  Interaction of porphyrins with heme proteins--a brief review.

Authors:  Abhay Sankar Chakraborti
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

4.  Three-dimensional fluence rate measurement and data acquisition system for minimally invasive light therapies.

Authors:  Benjamin Lai; Maxim Loshchenov; Alexander Douplik; Rob Rusnov; Marcos Jimenez-Davila; George Netchev; Lothar Lilge
Journal:  Rev Sci Instrum       Date:  2009-04       Impact factor: 1.523

5.  Automatic interstitial photodynamic therapy planning via convex optimization.

Authors:  Abdul-Amir Yassine; William Kingsford; Yiwen Xu; Jeffrey Cassidy; Lothar Lilge; Vaughn Betz
Journal:  Biomed Opt Express       Date:  2018-01-30       Impact factor: 3.732

6.  Quantification of in vivo fluorescence decoupled from the effects of tissue optical properties using fiber-optic spectroscopy measurements.

Authors:  Anthony Kim; Mamta Khurana; Yumi Moriyama; Brian C Wilson
Journal:  J Biomed Opt       Date:  2010 Nov-Dec       Impact factor: 3.170

Review 7.  New delivery approaches for pediatric brain tumors.

Authors:  Ian F Pollack; Robert Keating
Journal:  J Neurooncol       Date:  2005-12       Impact factor: 4.130

8.  Optical glucose analogs of aminolevulinic acid for fluorescence-guided tumor resection and photodynamic therapy.

Authors:  Eduardo H Moriyama; Weiguo Cao; Tracy W Liu; Han Lin Wang; Peter D Kim; Juan Chen; Gang Zheng; Brian C Wilson
Journal:  Mol Imaging Biol       Date:  2014-08       Impact factor: 3.488

9.  ALA- and ALA-ester-mediated photodynamic therapy of human glioma spheroids.

Authors:  Henry Hirschberg; Chung-Ho Sun; Bruce J Tromberg; Steen J Madsen
Journal:  J Neurooncol       Date:  2002-03       Impact factor: 4.130

10.  Protoporphyrin IX-induced structural and functional changes in human red blood cells, haemoglobin and myoglobin.

Authors:  Susmita Sil; Tania Bose; Dibyendu Roy; Abhay Sankar Chakraborti
Journal:  J Biosci       Date:  2004-09       Impact factor: 1.826

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.